Not Formula 1. FoundationOne CDx.

A month ago, I dropped €3,600 to have my tumor genetically profiled. Today I sat down with my oncologist to review the results. FoundationOne CDx analyzes hundreds of cancer-related genes in tumor tissue to identify driver mutations, biomarkers like MSI and TMB, FDA-approved targeted therapies, and clinical trial matches. It's a DNA-level blueprint of the cancer.

My results: KRAS G12V mutation, MSI-Stable, low tumor mutational burden (4 muts/Mb), HRD-negative, no BRAF or ERBB2 alterations.

Translation — the KRAS G12V mutation rules out a whole family of targeted drugs called EGFR inhibitors. The MSI and TMB results suggest immunotherapy is unlikely to work. No other actionable mutation showed up. No hidden shortcut in the genome.

No targeted therapies are available, but now we know exactly what won't work and what doors are closed. If standard treatment ever stops working, this genomic map is already built and documented. No delay, no scrambling.

Clinical trials aren't an option right now either — they're for patients whose standard therapies have failed. You don't experiment when the current plan is producing results, and right now FOLFIRI is shrinking the disease. The FoundationOne data goes into the back pocket, ready if we need to reach for it.

The plan: resume chemo in two days, re-image after three or four more treatments, and keep monitoring inflammation and liver enzymes. Because of elevated enzymes, the dosage is being reduced — treatment three was already cut by 30%. We're threading the needle between keeping enough pressure on the cancer without pushing the liver too hard.